Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 364

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 364
---
    Date(1)  
    ($)  
    ($)  
    ($)  
    (#)  
    (#)  
    (#)  
    (#)  
    (#)  
    ($/Sh)  
    ($/Sh)  

    Erez Aminov, CEO 
     8/27/2024  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     1,960,170(2) 
    $5.02(4) 
    $5.26  
    $7,513,332 
  
    Michelle Yanez, CFO 
     8/27/2024  
     -  
        
     -  
     -  
     -  
     -  
     -  
     200,000(3) 
    $5.02(4) 
    $5.26  
    $782,000 
  
    Christopher Chapman, former
    CEO 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     - 
  
    Nathen Fuentes, former CFO 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     - 

(1)
The “Grant Date” represents the date on which the Compensation Committee of the Board took action to grant the applicable
award

(2)
The stock awards disclosed in this item consist of options, as issued under our 2023 Omnibus Incentive Plan, which vest 50% at grant
date, and 50% six months from grant date.

(3)The
stock awards disclosed in this item consist of options, as issued under our 2023 Omnibus Incentive Plan, which vest ratably in fourths
every six months beginning February 2024

(4)
The Compensation Committee granted these stock awards using the closing price on 8/26/